With an increasing prevalence owing to aging populations, the major-market osteoporosis patient pool is large and growing. The combined influence of increased patient numbers and drug launches will support the market through 2030. However, market growth will be tempered by generic erosion of key brands. The relatively low diagnosis and drug-treatment rates for osteoporosis, owing to the asymptomatic nature of the disease, will also continue to hold back the market. Driven largely by their widespread generic availability and strong physician familiarity, bisphosphonates continue to dominate first-line treatment, creating a significant barrier to uptake for novel therapies. Emerging therapies will need to demonstrate a significant risk-clinical benefit balance, at a competitive price, to challenge the bisphosphonates as first-line treatments. Therefore, most emerging therapies will compete for use as second- or third-line treatments.
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.
Primary research: 20 country-specific interviews with experts.
Epidemiology: Prevalence of osteoporosis by country, with diagnosis and drug-treatment rates.
Population segments in market forecast: Osteoporosis.
Emerging therapies: Phase III: 1 drug; Phase II: 1 drug. Coverage of select preclinical and Phase I products.
Key drugs: Denosumab, teriparatide, abaloparatide SC, abaloparatide TD, alendronate, romosozumab, raloxifene.
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Disease Landscape & Forecast will feature continuous updates in 2021 to provide timely insights and analyses as meaningful indication-specific news and events unfold.